CDK7-IN-1

CDK7-IN-1 is an analog derived from YKL-5-124 and functions as an inhibitor of cyclin-dependent kinase 7 (cdk7). It exhibits strong inhibitory activity, with an IC50 value of less than 100 nM (WO 2016105528 A2, Compound 215).

THZ2 (CDK7-IN-1), an analog of THZ1, is a potent and selective CDK7 inhibitor(IC50:13.9 nM),with the potential to treat Triple-negative breast cancer (TNBC).

HDAC1 CDK7-IN-1 (compound 8e) is a dual inhibitor of CDK7 and HDAC1, with IC50 values of 893 nM and 248 nM, respectively. It suppresses the proliferation of cancer cell lines such as MDA-MB-231, MCF-7, A549, and HCT-116, induces cell cycle arrest and apoptosis in HCT-116 cells, and impedes their migration [1].

CDK7 9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7 9 (CDK7 9), targeting CDK7 with IC50 values of 0.0656 μM without pre-incubation and 0.00574 μM after 3 hours pre-incubation, and displaying inhibitory activity against CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation, making it valuable for cancer research.

CDK7-IN-16 (Compound 9) is a potent inhibitor of CDK 7 (IC50: 1-10 nM). CDK7-IN-16 can be used in research against cancer, particularly cancers with transcriptional abnormalities.

CDK7 12-IN-1 is a selective inhibitor of CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) and effectively inhibits tumor growth.

CDK7-IN-12 is an effective CDK7 inhibitor and plays a key role in regulating transcription and cell cycle. CDK7-IN-12 can effectively inhibit the proliferation of malignant tumors in vitro and in vivo. CDK7-IN-12 has research potential in cancer diseases.

CDK7-IN-13 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-13 has the potential to be investigated in a variety of cancers (particularly those with dysregulated transcription).

CDK7-IN-14 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-14 has the potential to be investigated in a variety of cancers, particularly those with transcriptional dysregulation.

CDK7-IN-15 is a pyrimidine-derived compound and a potent inhibitor of CDK7. CDK7-IN-15 has the potential to be investigated in a variety of cancers, particularly those with dysregulated transcription.

CDK7-IN-18 is a pyrimidine-derived compound that is a potent inhibitor of CDK7. CDK7-IN-18 exhibits potential for research in a variety of cancers, particularly those with dysregulated transcription.

CDK7-IN-17 is a pyrimidine-derived compound and a potent inhibitor of CDK7. CDK7-IN-17 has shown research potential for a variety of cancers, particularly those with dysregulated transcription.

CDK7-IN-10 is a CDK7 inhibitor (IC50 < 100 nM) that inhibits kinase activity, with potential to impede cell growth and induce apoptosis.

CDK7 9 tide is a peptide substrate for CDK7 or CDK9[1].

Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7 cyclin H Mat1 and Cdk9 cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7 9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively ind......

CDK7-IN-21 (compound A22) is a potent inhibitor of CDK7 [1].

CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor with demonstrated antitumor activity and specificity for CDK7 [1].

SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing cellular activity in triple-negative breast cancer MDA-MB-468 cells (IC50 = 6.6 nM) [1].

CDK7-IN-25 (CY-16-1) is a highly potent CDK7 inhibitor with an IC50 of less than 1nM, used in cancer research [1].